5 Reasons Why We Believe Novogen Is Poised For Success
- In preliminary tests, Novogen’s new drugs have shown to be able to kill the full hierarchy of cancer cells including cancer stem cells.
- The 5-year survival rate of cancer is low. The market has been anticipating a new drug that is able to improve those odds. Novogen is highly likely to achieve that.
- Novogen will apply for an IND submission for 2 drugs (possibly 3) in H2 2014. Hence, now is the best time to buy with the best risk/reward ratio.
- Novogen’s new drugs have a high probability to pass IND and do well in clinical trials.